TP53 mutations is an unfavorable prognostic factor in patients receiving first-, second-, and third-generation EGFR-TKI therapy with EGFR mutant advanced NSCLC [7, 11, 22, 23]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.